This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva seeks stay after US court denies rehearing in Orange Book patent dispute

By Nick Robertson ( March 5, 2025, 21:17 GMT | Insight) -- Teva Pharmaceuticals moved yesterday for a third stay in its patent suit against Amneal Pharmaceuticals, a day after the US Court of Appeals for the Federal Circuit denied Teva’s motion for en banc rehearing. The court previously affirmed a lower court’s ruling that Teva must delist five patents for inhaler devices. Teva intends to seek US Supreme Court review, and is seeking an immediate stay pending a decision from the high court on the company’s petition for review in order to avoid having to submit papers to the Food and Drug Administration delisting its patents from the agency's Orange Book.Teva Pharmaceuticals urged the US Court of Appeals for the Federal Circuit yesterday to grant a stay of its decision ordering the company to delist five of its inhaler device patents from the Food and Drug Administration’s Orange Book....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections